Analysis of the effectiveness and safety of maintenance treatment with intravenous ustekinumab in inflammatory bowel disease.

Autor:	Pampín Sánchez R; Farmacia Hospitalaria, Hospital Universitario de Cabueñes, España., Gonzalo González A; Farmacia Hospitalaria, Hospital Universitario de Cabueñes., Fuertes Camporro S; Farmacia Hospitalaria, Hospital Universitario de Cabueñes., Goenaga Ansola A; Farmacia Hospitalaria, Hospital Universitario de Cabueñes., Fórneas Sangil A; Farmacia Hospitalaria, Hospital Universitario de Cabueñes., Tembrás Martínez S; Farmacia Hospitalaria, Hospital Universitario de Cabueñes., Varela Trastoy P; Aparato Digestivo, Hospital Universitario de Cabueñes., Martínez-Múgica Barbosa C; Farmacia Hospitalaria, Hospital Universitario de Cabueñes.
Jazyk:	angličtina
Zdroj:	Revista espanola de enfermedades digestivas [Rev Esp Enferm Dig] 2024 Dec 04. Date of Electronic Publication: 2024 Dec 04.
DOI:	10.17235/reed.2024.10731/2024
Abstrakt:	Background and Purpose of the Study: Ustekinumab is a monoclonal antibody approved for the treatment of moderate to severe Crohn's disease (CD) and ulcerative colitis (UC). In spite of being an effective treatment, patients may have suboptimal response, or lose it over time. In these cases, ustekinumab intravenous (IV) maintenance therapy has been explored as a rescue option. Methods: Retrospective, monocentric, descriptive, observational study that included adult patients with inflammatory bowel disease who received maintenance therapy with intravenous ustekinumab after loss of response to intensified subcutaneous therapy. The primary outcome was a combination of clinical remission with biochemical and/or endoscopic response at week 12 after intravenous intensification. Results: 22 patients were included. The primary outcome was achieved in 36.36% of patients. At week 12, clinical remission was achieved in 40.91% of patients, and biochemical remission in 63.64%. The median HBI score in patients with CD decreased from 6 to 3 points at week 12 (p<0.001), and to 2 points at week 52 (p=0.004). After a median follow-up period of 31.46 months, 81.82% of patients continued their treatment with ustekinumab. No adverse events were reported. Conclusions: Maintenance therapy with intravenous ustekinumab seems to be effective and safe for the rescue of patients with CD and UC who lost response to intensified subcutaneous ustekinumab.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu